Glipizide extended-release tablets

This product is a second-generation sulfonylurea oral hypoglycemic drug. It can promote the secretion of insulin by pancreatic beta cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic alpha cells to inhibit the secretion of glucagon, inhibit the decomposition of liver glycogen, and promote muscle utilization and consumption of glucose.

This product mainly contains: Glipizide

This product is a slightly yellow film-coated tablet, which appears white or off-white after removing the film coating.

Used for type 2 diabetes.

Oral administration requires swallowing the whole tablet. The dosage varies from person to person. The recommended starting dose is 5 mg/day, once a day, 30 minutes before breakfast. The dosage and medication time can be adjusted according to blood sugar levels.

1. The most common symptoms are gastrointestinal symptoms (such as nausea, upper abdominal distension), headache, etc., which can be relieved by reducing the dose. 2. Some patients may experience skin allergies. 3. Hypoglycemia is occasionally seen, especially in the elderly and weak, those who are overactive, those who eat irregularly, drink alcohol, or have liver damage. 4. There are also occasional reports of reversible changes in the hematopoietic system.

1. Type 1 diabetes, diabetic ketoacidosis, pre-diabetic coma or coma. 2. Patients with liver dysfunction, adrenal insufficiency and allergic to this product are contraindicated.

Precautions for children: Not clear yet. Precautions for pregnancy and lactation: Although animal experiments have not found teratogenic effects, there is a lack of clinical data, so pregnant and lactating women should not use it. Precautions for the elderly: Start with a small dose and gradually adjust the dose.

1. This drug can increase its hypoglycemic effect when used in combination with coumarins, monoamine oxidase inhibitors, phenylbutazone, sulfonamides, chloramphenicol, cyclophosphamide, probenecid, and salicylic acid drugs. 2. When used in combination with adrenaline, adrenocortical hormones, oral contraceptives, and thiazide diuretics, its hypoglycemic effect can be reduced. 3. Be cautious when used in combination with B-blockers. 4. Gastrointestinal diseases that shorten the retention time of this product in the gastrointestinal tract can affect the pharmacokinetics and efficacy of this product.

Keep away from light and store in sealed container.

5 mg

18 months.

Yangtze River Pharmaceutical (Group) Co., Ltd.

• Founded in:

  2001-03-27

• Address:

  No. 1, South Yangtze River Road, Taizhou

• Tax NO.:

  913212007286987632

• Registered Funds:

  133 million yuan

• Website:

  Log in to view

• Email:

  Log in to view